SRV Hospitals secures Rs 140 Cr from InvAscent

IMT News Desk
IMT News Desk
· 2 min read

To augment the critical care-backed model

SRV Hospitals has raised Rs 140 crores from InvAscent, India’s leading life sciences private equity fund. The investment will enable SRV to strengthen and amplify its multispecialty critical care-focussed healthcare model. The funding positions SRV for its next chapter, setting new benchmarks in the healthcare sector, while deepening its commitment to advanced critical and surgical care, empowered clinicians, and elevated patient experience.

“We built SRV Hospitals with a vision of setting new standards in the critical and surgical care space, and those standards have now become our greatest strength,” said Dr Abhay Vispute, Director – SRV Hospitals. “This investment from InvAscent is a strategic alignment of purpose. Over these years, SRV has grown with intent, delivered excellence with consistency, and built trust with one patient, one family, and one neighbourhood at a time. This capital will strengthen our core and extend our impact.”

Sameer Pawar, CEO, SRV Hospitals, said, “Our mission is rooted in the belief that high-quality care should not be a privilege of geography. We’ve created hospital ecosystems that bring empathy, expertise, and innovation to people’s neighbourhoods. This investment allows us to strengthen our mission responsibly—with our people, our standards, and our commitment to trust at the centre of it all.”

“We are proud to partner with SRV Hospitals, a group that has a strong foundation and boasts a high-trust clinical network backed by a differentiated critical care model, and a leadership team that is not only clinically astute and operationally strong but deeply aligned with the long-term evolution of healthcare in this country,” said Dr Jeevak Gupta, Director – Investments,  InvAscent.

Read Next

Granules India posts Rs 13,879 million revenue from operations at Q3FY26
Finance
January 28, 2026

Granules India posts Rs 13,879 million revenue from operations at Q3FY26

Net debt stood at Rs 10,151 million and net debt to EBITDA at 0.91x Granules India has announced its financial results for the quarter ended December 31, 2025. Revenue from Operations of Q3FY26 stood at Rs 13,879 million, a growth of 22 per cent YoY driven by Finished Dosages (FD) segment in North America and […]
Article by: IMT News Desk
OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26
Finance
January 28, 2026

OneSource Pharma’s revenue down at Rs 2,903 million in Q3FY26

Impacted by delayed semaglutide approvals in Canada OneSource has posted the Q3FY26 results. Revenues were at Rs 2,903 million, down 26 per cent YoY, impacted by delayed semaglutide approvals in Canada. The EBITDA was at Rs 173 million, down 88 per cent YoY, due to lower revenue in the quarter and largely fixed cost base. […]
Article by: IMT News Desk
Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr
Finance
January 27, 2026

Syngene International’s Q3 revenue from operations dip 3% year-on-year to Rs 917 Cr

Reported revenue dips to Rs 932 crore in the same quarter Syngene International announced financial results for the third quarter of FY26. Peter Bains, Managing Director and CEO, Syngene International, said, “Our Q3 performance reflects the ongoing impact related to a single product from one of our large-molecule biologics clients. Outside of this factor, the […]
Article by: IMT News Desk
Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427
Finance
January 27, 2026

Sigachi Industries aims to increase revenue potential by Rs 250 cr commencing from Q427

Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility Sigachi Industries announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks […]
Article by: IMT News Desk